State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Oral & Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P.R. China.
Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of Southwest Medical University, Luzhou 646000, P.R. China.
ACS Appl Mater Interfaces. 2021 Jun 30;13(25):29439-29449. doi: 10.1021/acsami.1c08565. Epub 2021 Jun 17.
In a search for a solution to large-area soft and hard tissue defects, whether or not tissue regeneration or tissue-substitutes transplantation is used, the problems with angiogenesis need to be solved urgently. Thus, a new and efficient proangiogenic approach is needed. Nanoengineering systems have been considered one of the most promising approaches. In this study, we modify the tetrahedral framework nucleic acid (tFNA) for the first time with two different angiogenic DNA aptamers to form aptamer-tFNA nanostructures, tFNA-Apt02 and tFNA-AptVEGF, and the effects of them on angiogenesis both in vitro and in vivo are investigated. We develop new nanomaterials for enhancing angiogenesis to solve the problem of tissue engineering vascularization and ischemic diseases. The results of our study confirm that tFNA-Apt02 and tFNA-AptVEGF has a stronger ability to accelerate endothelial cell proliferation and migration, tubule formation, spheroid sprouting, and angiogenesis in vivo. We first demonstrate that the engineered novel tFNA-Apt02 and tFNA-AptVEGF have promoting effects on angiogenesis both in vitro and in vivo and provide a theoretical basis and opportunity for their application in tissues engineering vascularization and ischemic diseases.
在寻找大面积软、硬组织缺损的解决方案时,无论是否使用组织再生或组织替代物移植,都急需解决血管生成问题。因此,需要一种新的、有效的促血管生成方法。纳米工程系统被认为是最有前途的方法之一。在这项研究中,我们首次对四面体框架核酸(tFNA)进行修饰,用两种不同的血管生成 DNA 适体形成适体-tFNA 纳米结构,tFNA-Apt02 和 tFNA-AptVEGF,并研究它们在体外和体内对血管生成的影响。我们开发新的纳米材料来增强血管生成,以解决组织工程血管化和缺血性疾病的问题。我们的研究结果证实,tFNA-Apt02 和 tFNA-AptVEGF 具有更强的促进内皮细胞增殖和迁移、管状形成、球体发芽和体内血管生成的能力。我们首次证明,工程化的新型 tFNA-Apt02 和 tFNA-AptVEGF 具有促进体外和体内血管生成的作用,为它们在组织工程血管化和缺血性疾病中的应用提供了理论依据和机会。